The MedQIA Imaging Biomarker Informatics System (IBIS), the FDA 510(k) cleared software toolkit employs a model-based engine to segment the lung, lobes, segments and airways and has been applied in our supported lung studies to date, currently more than fifty (50) in-house and numerous others with our academic partners. MedQIA’s Diffuse Lung Disease (DLD) Panel includes quantitative measures of alveola opacification for assessment of acute lung involvement and shows potential to explore Prediction of Change from baseline imaging and measure change on follow up Imaging. Additionally, our DLD panel includes our well-validated Quantitative Lung Fibrosis (QLF) biomarker measurement, which can assess the fibrosis associated with medium to long-term pulmonary fibrosis associated with COVID-19, including Advanced Respiratory Disease (ARDS).